{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:10:33Z","timestamp":1759453833255,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.ccm.2005.02.003","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T09:54:25Z","timestamp":1113472465000},"page":"313-326","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Latent Tuberculosis Infection: Challenges and Prospects"],"prefix":"10.1016","volume":"26","author":[{"given":"Kelly E.","family":"Dooley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccm.2005.02.003_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2005.02.003_bib2","first-page":"1","article-title":"Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli","volume":"19","author":"Sutherland","year":"1976","journal-title":"Adv Tuberc Res"},{"key":"10.1016\/j.ccm.2005.02.003_bib3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence","volume":"99","author":"Comstock","year":"1974","journal-title":"Am J Epidemiol"},{"issue":"20","key":"10.1016\/j.ccm.2005.02.003_bib4","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1056\/NEJMsa031667","article-title":"Priorities for the treatment of latent tuberculosis infection in the United States","volume":"350","author":"Horsburgh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib5","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1164\/ajrccm.157.3.9708002","article-title":"The host immune response to tuberculosis","volume":"157","author":"Schluger","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib6","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"year":"2000","series-title":"Ending neglect: the elimination of tuberculosis in the United States","key":"10.1016\/j.ccm.2005.02.003_bib7"},{"issue":"12","key":"10.1016\/j.ccm.2005.02.003_bib8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/82139","article-title":"Latent Mycobacterium tuberculosis\u2014persistence, patience, and winning by waiting","volume":"6","author":"Manabe","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib9","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"issue":"10","key":"10.1016\/j.ccm.2005.02.003_bib10","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00002030-199903110-00009","article-title":"Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Bucher","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.ccm.2005.02.003_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0140-6736(93)91817-6","article-title":"Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection","volume":"342","author":"Pape","year":"1993","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ccm.2005.02.003_bib13","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.1997.00440360155017","article-title":"Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival","volume":"157","author":"Moreno","year":"1997","journal-title":"Arch Intern Med"},{"issue":"16","key":"10.1016\/j.ccm.2005.02.003_bib14","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1097\/00002030-200111090-00008","article-title":"Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil","volume":"15","author":"de Pinho","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ccm.2005.02.003_bib15","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ccm.2005.02.003_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002030-200101260-00011","article-title":"Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults","volume":"15","author":"Quigley","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.ccm.2005.02.003_bib17","first-page":"490","article-title":"Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts","volume":"85","author":"Ferebee","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib18","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.7326\/0003-4819-71-6-1113","article-title":"Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid","volume":"71","author":"Scharer","year":"1969","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-81-2-200","article-title":"The effect of isoniazid on transaminase levels","volume":"81","author":"Bailey","year":"1974","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1378\/chest.68.2.181","article-title":"Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy","volume":"68","author":"Mitchell","year":"1975","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2005.02.003_bib21","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0022-3476(76)80949-3","article-title":"Isoniazid hepatitis in adolescents","volume":"89","author":"Litt","year":"1976","journal-title":"J Pediatr"},{"key":"10.1016\/j.ccm.2005.02.003_bib22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1001\/jama.1972.03200110051009","article-title":"Isoniazid toxicity. A prospective study in secondary chemoprophylaxis","volume":"220","author":"Byrd","year":"1972","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2005.02.003_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00004836-198109000-00012","article-title":"Risk factors for isoniazid (INH)-induced liver dysfunction","volume":"3","author":"Dickinson","year":"1981","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.ccm.2005.02.003_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.1979.03290380015017","article-title":"Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients","volume":"241","author":"Byrd","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2005.02.003_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/515221","article-title":"Isoniazid toxicity in health care workers","volume":"28","author":"Stuart","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib26","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service Cooperative Surveillance Study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2005.02.003_bib28","first-page":"1039","article-title":"Isoniazid preventive therapy","volume":"121","author":"Dash","year":"1980","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib29","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1164\/ajrccm\/145.2_Pt_1.494","article-title":"Isoniazid-associated hepatitis deaths: a review of available information","volume":"145","author":"Snider","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib30","first-page":"457","article-title":"The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis","volume":"29","year":"1963","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0041-3879(80)90038-0","article-title":"Pyridoxine supplementation during isoniazid therapy","volume":"61","author":"Snider","year":"1980","journal-title":"Tubercle"},{"key":"10.1016\/j.ccm.2005.02.003_bib32","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00005792-199507000-00005","article-title":"Correlates of hepatitis C virus infections among injection drug users","volume":"74","author":"Thomas","year":"1995","journal-title":"Medicine"},{"issue":"10","key":"10.1016\/j.ccm.2005.02.003_bib34","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1086\/323896","article-title":"Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis","volume":"33","author":"Sadaphal","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ccm.2005.02.003_bib35","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1086\/345906","article-title":"Isoniazid hepatotoxicity among drug users: the role of hepatitis C","volume":"36","author":"Fernandez-Villar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","article-title":"Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ccm.2005.02.003_bib37","first-page":"289","article-title":"Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection\u2014New York and Georgia, 2000","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ccm.2005.02.003_bib38","first-page":"733","article-title":"Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC recommendations\u2014United States, 2001","volume":"50","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ccm.2005.02.003_bib39","first-page":"735","article-title":"Update. Adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ccm.2005.02.003_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.ccm.2005.02.003_bib41","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","article-title":"Twice weekly tuberculosis preventive therapy in HIV infection in Zambia","volume":"12","author":"Mwinga","year":"1998","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib42","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/422724","article-title":"Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?","volume":"39","author":"Gordin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","year":"1992","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"10.1016\/j.ccm.2005.02.003_bib44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/adc.78.2.169","article-title":"Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis","volume":"78","author":"Ormerod","year":"1998","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.ccm.2005.02.003_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1378\/chest.99.2.465","article-title":"Toxic hepatitis with isoniazid and rifampin. A meta-analysis","volume":"99","author":"Steele","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2005.02.003_bib46","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1164\/ajrccm.154.5.8912767","article-title":"Rifampin preventive therapy for tuberculosis in Boston's homeless","volume":"154","author":"Polesky","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib47","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1164\/ajrccm.155.5.9154885","article-title":"Rifampin preventive therapy for tuberculosis infection. Experience with 157 adolescents","volume":"155","author":"Villarino","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib49","first-page":"773","article-title":"Isoniazid prophylaxis in Alaskan boarding schools: a comparison of two doses","volume":"100","author":"Comstock","year":"1969","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM196110122651501","article-title":"Preventive effects of isoniazid in the treatment of primary tuberculosis in children","volume":"265","author":"Mount","year":"1961","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib51","first-page":"61","article-title":"Management of persons exposed to multidrug-resistant tuberculosis","volume":"41","year":"1992","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"10.1016\/j.ccm.2005.02.003_bib52","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/clinids\/24.6.1264","article-title":"Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin","volume":"24","author":"Ridzon","year":"1997","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.ccm.2005.02.003_bib53","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2005.02.003_bib54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","article-title":"Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management","volume":"3","author":"Gardam","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib55","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor-alpha\u2014California, 2002-2003","volume":"53","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ccm.2005.02.003_bib56","first-page":"685","article-title":"Missed opportunities for prevention of tuberculosis among persons with HIV infection\u2014selected locations, United States, 1996-1997","volume":"49","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00007611-200295040-00009","article-title":"Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States","volume":"95","author":"Reichler","year":"2002","journal-title":"South Med J"},{"issue":"3","key":"10.1016\/j.ccm.2005.02.003_bib58","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1378\/chest.119.3.833","article-title":"Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates","volume":"119","author":"Bock","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2005.02.003_bib59","first-page":"222","article-title":"Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection\u2014Chickasaw County, Mississippi, June 1999-March 2002","volume":"52","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.ccm.2005.02.003_bib60","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-137-8-200210150-00007","article-title":"Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial","volume":"137","author":"Jasmer","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib61","first-page":"979","article-title":"Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia","volume":"2","author":"Heal","year":"1998","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S0002-9343(01)00695-7","article-title":"A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users","volume":"110","author":"Chaisson","year":"2001","journal-title":"Am J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.ccm.2005.02.003_bib63","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1164\/ajrccm.157.5.9709072","article-title":"Once-weekly rifapentine-containing regimens for treatment of tuberculosis in mice","volume":"157","author":"Grosset","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib64","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0140-6736(02)09742-8","article-title":"Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomized clinical trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ccm.2005.02.003_bib65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1164\/rccm.200310-1380OC","article-title":"Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis","volume":"169","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib66","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1164\/rccm.200407-885OC","article-title":"Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis","volume":"170","author":"Nuermberger","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2005.02.003_bib67","first-page":"821","article-title":"The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis","volume":"85","author":"Mount","year":"1962","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib68","first-page":"161","article-title":"A controlled trial of isoniazid prophylaxis in mental institutions","volume":"88","author":"Ferebee","year":"1963","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib69","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska","volume":"95","author":"Comstock","year":"1967","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib70","first-page":"91","article-title":"Chemoprophylaxis of tuberculosis for adults in Japan","volume":"69","author":"Chiba","year":"1963","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.ccm.2005.02.003_bib71","unstructured":"Nyboe J., Farah A.R., Christensen O.W. Report on tuberculosis chemotherapy pilot project (Tunisia 9). WHO\/TB\/Tech Information\/10. April 22, 1963."},{"key":"10.1016\/j.ccm.2005.02.003_bib72","first-page":"419","article-title":"The use of isoniazid among household contacts of open cases of pulmonary tuberculosis","volume":"33","author":"Egsmose","year":"1965","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ccm.2005.02.003_bib73","first-page":"277","article-title":"Chemoprophylaxis in the Philippines. A controlled pilot study among household contacts of tuberculosis cases","volume":"7","author":"Del Castillo","year":"1965","journal-title":"Bulletin of the Quezon Institute"},{"key":"10.1016\/j.ccm.2005.02.003_bib74","first-page":"509","article-title":"Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland","volume":"35","author":"Horwitz","year":"1966","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.ccm.2005.02.003_bib75","first-page":"169","article-title":"Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults","volume":"41","author":"Veening","year":"1968","journal-title":"Bull Int Union Tuberc"},{"issue":"7","key":"10.1016\/j.ccm.2005.02.003_bib76","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00002030-199707000-00006","article-title":"Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial","volume":"11","author":"Hawken","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.ccm.2005.02.003_bib77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199707313370505","article-title":"A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis","volume":"337","author":"Gordin","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ccm.2005.02.003_bib78","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00042560-200111010-00018","article-title":"No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial","volume":"28","author":"Fitzgerald","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ccm.2005.02.003_bib79","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/arrd.1973.107.4.523","article-title":"Disturbed hepatic function during isoniazid prophylaxis","volume":"107","author":"Bailey","year":"1973","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ccm.2005.02.003_bib80","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1001\/archinte.1977.03630210016007","article-title":"Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity","volume":"137","author":"Byrd","year":"1977","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.ccm.2005.02.003_bib81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.288.2.165","article-title":"Safety and tolerability of intermittent rifampin\/pyrazinamide for the treatment of latent tuberculosis infection in prisoners","volume":"288","author":"Chaisson","year":"2002","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ccm.2005.02.003_bib82","first-page":"995","article-title":"Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics","volume":"6","author":"Lee","year":"2002","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2005.02.003_bib83","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","article-title":"Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity","volume":"123","author":"McNeill","year":"2003","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2005.02.003_bib84","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1164\/rccm.200209-998OC","article-title":"Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis","volume":"167","author":"Stout","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib85","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1086\/422645","article-title":"Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment","volume":"39","author":"van Hest","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ccm.2005.02.003_bib86","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1378\/chest.122.4.1292","article-title":"Short-course rifamycin and pyrazinamide treatment for latent tuberculosis infection in patients with HIV infection: the 2-year experience of a comprehensive community-based program in Broward County, Florida","volume":"122","author":"Narita","year":"2002","journal-title":"Chest"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523105000043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523105000043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:32:36Z","timestamp":1759451556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523105000043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0272523105000043"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2005.02.003","relation":{},"ISSN":["0272-5231"],"issn-type":[{"type":"print","value":"0272-5231"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Latent Tuberculosis Infection: Challenges and Prospects","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2005.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}